JP2019529481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529481A5 JP2019529481A5 JP2019516972A JP2019516972A JP2019529481A5 JP 2019529481 A5 JP2019529481 A5 JP 2019529481A5 JP 2019516972 A JP2019516972 A JP 2019516972A JP 2019516972 A JP2019516972 A JP 2019516972A JP 2019529481 A5 JP2019529481 A5 JP 2019529481A5
- Authority
- JP
- Japan
- Prior art keywords
- theta
- crystalline form
- compound
- crystal
- starting temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013078 crystal Substances 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 18
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 18
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000003828 vacuum filtration Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402813P | 2016-09-30 | 2016-09-30 | |
| US62/402,813 | 2016-09-30 | ||
| PCT/US2017/054227 WO2018064441A1 (en) | 2016-09-30 | 2017-09-29 | Crystalline forms of a bile acid derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529481A JP2019529481A (ja) | 2019-10-17 |
| JP2019529481A5 true JP2019529481A5 (OSRAM) | 2020-09-17 |
Family
ID=61760943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516972A Withdrawn JP2019529481A (ja) | 2016-09-30 | 2017-09-29 | 胆汁酸誘導体の結晶形態 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200024299A1 (OSRAM) |
| EP (1) | EP3518937A4 (OSRAM) |
| JP (1) | JP2019529481A (OSRAM) |
| KR (1) | KR20190057108A (OSRAM) |
| CN (1) | CN109963567A (OSRAM) |
| AU (1) | AU2017336803A1 (OSRAM) |
| BR (1) | BR112019006242A2 (OSRAM) |
| CA (1) | CA3038534A1 (OSRAM) |
| IL (1) | IL265621A (OSRAM) |
| MX (1) | MX2019003684A (OSRAM) |
| WO (1) | WO2018064441A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008002573A2 (en) * | 2006-06-27 | 2008-01-03 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions |
| CN101528752A (zh) * | 2006-10-16 | 2009-09-09 | 辉瑞产品公司 | 治疗性吡唑基噻吩并吡啶 |
| JP5441705B2 (ja) * | 2007-10-15 | 2014-03-12 | 武田薬品工業株式会社 | アミド化合物およびその用途 |
| EP2468762A1 (en) * | 2010-11-30 | 2012-06-27 | Dr. Falk Pharma Gmbh | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size |
| ES2822375T3 (es) * | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
| WO2014066819A1 (en) * | 2012-10-26 | 2014-05-01 | Intercept Pharmaceuticals, Inc. | Process for preparing bile acid derivatives |
| KR102106186B1 (ko) * | 2012-11-28 | 2020-05-04 | 인터셉트 파마슈티컬즈, 인크. | 폐 질환의 치료 |
| HUP1300504A2 (en) * | 2013-08-27 | 2015-03-30 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sorafenib salts |
| BR112018002499A2 (pt) * | 2015-08-07 | 2018-09-18 | Intercept Pharmaceuticals Inc | método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica |
| KR20180052756A (ko) * | 2015-09-24 | 2018-05-18 | 인터셉트 파마슈티컬즈, 인크. | 담즙산 유도체 제조를 위한 방법 및 중간체 |
-
2017
- 2017-09-29 WO PCT/US2017/054227 patent/WO2018064441A1/en not_active Ceased
- 2017-09-29 AU AU2017336803A patent/AU2017336803A1/en not_active Abandoned
- 2017-09-29 US US16/337,982 patent/US20200024299A1/en not_active Abandoned
- 2017-09-29 MX MX2019003684A patent/MX2019003684A/es unknown
- 2017-09-29 EP EP17857474.5A patent/EP3518937A4/en not_active Withdrawn
- 2017-09-29 BR BR112019006242A patent/BR112019006242A2/pt not_active IP Right Cessation
- 2017-09-29 JP JP2019516972A patent/JP2019529481A/ja not_active Withdrawn
- 2017-09-29 KR KR1020197012131A patent/KR20190057108A/ko not_active Withdrawn
- 2017-09-29 CN CN201780071347.7A patent/CN109963567A/zh active Pending
- 2017-09-29 CA CA3038534A patent/CA3038534A1/en not_active Abandoned
-
2019
- 2019-03-26 IL IL265621A patent/IL265621A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529481A5 (OSRAM) | ||
| JP4138886B2 (ja) | ２−アミノ−４−（４−フルオルベンジルアミノ）−１−エトキシカルボニル−アミノベンゼンの新規変態ならびにその製造法 | |
| JP2018531963A5 (OSRAM) | ||
| JP2020511461A5 (OSRAM) | ||
| EP2785701B1 (en) | Crystalline form of carbazitaxel and process for preparation thereof | |
| JP2014501282A5 (OSRAM) | ||
| JP2014521726A5 (OSRAM) | ||
| JP2011513485A5 (OSRAM) | ||
| JP2007532560A5 (OSRAM) | ||
| JP7473486B2 (ja) | Ｒａｄ１９０１－２ｈｃｌの多形形態 | |
| JP2010535742A5 (OSRAM) | ||
| JP2015010091A5 (OSRAM) | ||
| RU2015103065A (ru) | Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения | |
| JP2018516883A5 (OSRAM) | ||
| CN104945375A (zh) | 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体 | |
| RU2017142958A (ru) | Кристаллы азабициклического соединения | |
| JP2015516425A5 (OSRAM) | ||
| JP2013520488A5 (OSRAM) | ||
| JP2009534373A5 (OSRAM) | ||
| AU2014259029A1 (en) | Polymorphic forms of nilotinib hydrochloride | |
| WO2014118808A2 (en) | Ticagrelor solid dispersion | |
| JP2013505234A (ja) | ３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンの固形体およびその製造方法 | |
| JPWO2020069024A5 (OSRAM) | ||
| JP2005529084A5 (OSRAM) | ||
| HK1206733A1 (en) | Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide |